With current techniques, AMkL can be readily diagnosed based on the identification of surface expression of platelet associated membrane antigens (glycoprotein IIb/IIIa) and associated bone marrow fibrosis. [3] AMkL is estimated to represent 3-14.6% of pediatric AML cases and 1% of adult AML cases. [4] [5] [6] The majority of AMkL cases are not characterized by particular chromosomal alterations, although infant AMkL cases frequently contain the translocation, t(1;22)(p13;q13). [7] AMkL cases may occur as secondary leukemias and have also been associated with mediastinal germ cell tumors. [5, 8] Down syndrome (DS) children have a significantly increased risk of developing both acute lymphoblastic leukemia (ALL) and AML compared to non-DS children. [9] DS AML cases have unique biological features including a predominance of the AMkL phenotype and significantly higher event-free survival (EFS) rates and lower relapse rates compared to non-DS AML patients treated with cytosine arabinoside (ara-C)-based protocols. [9] Zipursky has estimated that DS children have a 500-fold greater risk of developing AMkL compared to non-DS children. [10] We previously described a relationship between the expression of the gene, cystathionine-ß-synthase (CBS; localized to 21q22.3) and increased in vitro and in vivo ara-C sensitivity of DS myeloblasts over non-DS myeloblasts. [11, 12] CBS catalyzes the condensation of serine and homocysteine to form cystathionine, and increased CBS activity may have downstream effects on reduced folate and S-adenosylmethionine pathways, resulting in increased ara-C sensitivity. CBS only.
For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From 5 transcript levels in DS myeloblasts were a median 12-fold higher (far exceeding levels predicted by the gene dosage of 3 copies of the CBS gene in DS cells) than for non-DS myeloblasts, and CBS transcripts correlated with the generation of ara-C triphosphate (ara-CTP), the active intracellular ara-C metabolite, following in vitro incubations with 3 H-ara-C. [12] These results were recently replicated in a CBS-transfected leukemia cell line (CCRF-CEM) model. [13] The human CBS gene spans over 30 kilobases consisting of 23 exons and the CBS polypeptide is encoded by exons 1-14 and 16. [14] Our recent studies began to explore the transcriptional regulation of the CBS gene in non-AML cells and demonstrated important transactivating roles for critical transcription factors, including Sp1/Sp3, NF-Y, and USF1. [15, 16] In this study, we extended these results to clinically relevant DS and non-DS AMkL cell lines, in order to better understand the molecular bases for variations in CBS gene expression in AML and, potentially, the high EFS rates of DS AML patients. Identifying mechanisms of differential expression of chromosome 21-localized genes in DS cells could also provide insights into leukemogenesis in DS and the DS phenotype, in general.
MATERIALS AND METHODS

Chemicals and Reagents
[γ-32 P] ATP (3000 Ci/mmol) was purchased from Dupont-New England Nuclear (Boston, MA). Synthetic oligonucleotides were purchased from Genosys Biotechnologies (The Woodlands, TX).
Restriction and modifying enzymes, reporter gene vectors (pGL3-Basic, pRLSV40), and other molecular biologicals were purchased from Promega (Madison, WI The HepG2 human hepatocellular carcinoma cell line was obtained from ATCC and cultured as previously described. [16] The DS AMkL cell line, CMK (established from a 1 year old DS boy with AMkL), [17] was obtained from the German Collection of Microorganisms and Cell Cultures while the non-DS AMkL cell line, CMS (established from a 2 year old non-DS girl with AMkL), [17] was a gift from Dr. A. Fuse, (National Institute of Infectious Diseases, Tokyo, Japan). The CMK and CMS cell lines were maintained in RPMI 1640 containing 10% heat-inactivated iron-supplemented calf serum (Hyclone Labs), 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere at 37 o C in the presence of 5% CO 2 /95% air. The megakaryocytic phenotypes of the CMK and CMS cell lines were confirmed by flow cytometric analysis.
Reverse Transcriptase-PCR (RT-PCR) Analysis of CBS Transcripts
Total RNAs were isolated from 5 x 10 6 HepG2, CMK, and CMS cells using TRIzol reagent (Life Technology). RT-PCR was performed as previously described. [16] Levels of CBS transcripts were normalized to the levels of 18S ribosomal RNA (localized to chromosome 13; Ambion Inc, Austin, TX).
Rapid Amplification of 5'-cDNA Ends (5'-RACE) Assay
5'-RACE was performed using a 5'-RACE system (version 2.0; Life Technologies, Inc.) and total RNAs from the leukemia cell lines, CMK and CMS, as previously described. [16] In Vitro Drug Cytotoxicity Assay
For the determination of cytotoxicity, the DS and non-DS leukemia cell lines were cultured in complete medium with dialyzed calf serum in 24-well plates at a density of 50,000 cells/ml of media.
Cells were cultured continuously with a range of concentration of ara-C at 37°C and the cell numbers were counted after 4 days with trypan blue staining. The IC 50 values were calculated as the concentration of drug necessary to inhibit 50% growth compared to control cells grown in the absence of drug.
only.
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Ara-C Incubations and Measurement of ara-CTP
Incubation of leukemia cells with 3 H-ara-C and the measurement of intracellular ara-CTP levels were performed as previously described.
[11]
Construction of Luciferase Plasmids and Site Directed Mutagenesis
The full length CBS -1b promoter reporter gene construct pCBSb-4046/-3565, and the CAATbox, E-box, GC-and GT-box mutated CBS -1b promoter constructs were generated as previously described. [15, 16] Mutation primers are summarized in Table 1 .
Transient Transfections and Luciferase Assays
CBS-luciferase reporter gene constructs in pGL3Basic or the promoterless vector (5 µg) were cotransfected with 250 ng of pRLSV40 (Promega) into 5 x 10 6 CMK and CMS cells (in 1 ml of OptiMem) using Lipofectin reagent (Life Technologies) in accordance with the manufacturer's protocols.
Lipofectin treatments were for 24 h and, after an additional 48 h of incubation in complete medium, cells were harvested and lysates prepared. Firefly luciferase activities were assayed with a DualLuciferase Reporter Assay System (Promega) in a Turner TD20/20 luminometer and normalized to Renilla luciferase activity.
Preparation of Nuclear Extracts and Electromobility Shift Assays (EMSA)
Nuclear extracts from CMK and CMS cells were prepared as previously described. [15, 16] Complementary single-stranded oligonucleotides (Table 1) were annealed, end labeled with 32 P, and purified using Sephadex G-25 quick spin columns (Boehringer-Mannheim). Nuclear proteins were preincubated in a reaction buffer containing 20 mM Tris-HCl, pH 7.9, 2 mM MgCl 2, 1 mM EDTA, 50 mM KCl, 0.5 mM dithiothreitol, 10 % glycerol, 0.1% Nonidet P-40, and 2 µg of poly(dI-dC). After 10 min, the 32 P-end-labeled duplex oligonucleotide (2 x 10 5 cpm) was added, and the reaction was incubated for another 20 min on ice. DNA/protein complexes were separated on 5% non-denaturing only.
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Chromatin Immunoprecipitation (ChIP) Assay
We used a modification of the technique described by Boyd and Farnham. For personal use at PENN STATE UNIVERSITY on February 21, 2013. bloodjournal.hematologylibrary.org From 9 used in each PCR. Total input samples were resuspended in 100 µl of sterile H 2 O and then diluted 1:100 before PCR.
Standard PCR for the CBS -1b promoter region spanning the basal and the upstream elements was performed with a sense primer (5'-GAATCAACAGGGCGTGGGAATGGGG-3'; positions -3897 to -3921) and semi-nested antisense primers (5'-AGGCGGAGACGGCGACCCC-3' and 5'-GCGAGGGGAGCAGGCGGGCGGTGATTG-3; positions -3625 to -3643 and -3671 to -3697, respectively). Final PCR products were analyzed on agarose gels (2%) with ethidium bromide staining.
Western Blot Analysis
Nuclear proteins were isolated from CMK and CMS cells, as described above. Fifty µg aliquots of each nuclear protein or 100 µg aliquots of each cellular extract were fractionated on a polyacrylamide gel (7.5% for Sp1 and Sp3; 12% for USF1 and NF-YA; 10% for CBS) with SDS and eletroblotted onto a polyvinylidene difluoride (PVDF) membranes. The blots were blocked overnight at room temperature in TTBS [(Tween Tris-based saline with 0.1% Tween 20 (pH 7.5)] containing 1% fat-free dried milk powder and were then incubated with Sp1 (rabbit polyclonal antibody, Geneka), Sp3, USF-1, NF-YA (rabbit polyclonal antibody, Santa Cruz) antibodies or CBS antiserum, respectively, in TTBS containing 0.5% fat-free dried milk powder for 2h at room temperature. The blots were washed with TTBS and incubated with a second antibody (goat anti-rabbit IgG linked to horseradish peroxidase conjugate, diluted 1:5000 in TTBS-0.5% milk powder) for 1h at room temperature, and detected by Lumi-Light Western Blotting Substrate (Roche Diagnostics Corporation, Indianapolis, IN).
Dephosphorylation of Nuclear Extracts
Nuclear extracts of CMK cells (100 µg) were incubated with or without 20 units of calf alkaline phosphatase (Promega) for 1 hour at 37 °C in a total volume of 30µl. The reactions were stopped by the addition of a mixture of phosphatase inhibitors. [15] Ten micrograms of the treated nuclear extract were used for EMSA, as described above. 
RESULTS
CBS Gene Expression in CMK and CMS Cells
Our earlier studies documented the differential expression of CBS transcribed exclusively from the CBS -1b promoter in clinical DS and non-DS myeloblasts. [19] The DS AMkL cell line, CMK, and non-DS AMkL cell line, CMS, appeared to closely resemble the primary AML specimens from patients since CBS transcripts were readily detected by RT-PCR in the CMK cells, though they were undetectable in the CMS cells. [ Figure 1A ] Similar results were obtained by Western blot analysis of CBS protein levels in the CMK and CMS cells [ Figure 1B ].
Rapid amplification of 5'-cDNA ends (5'-RACE) assay was performed to confirm whether the CBS transcripts were transcribed from the CBS -1b promoter, as with the primary patient samples.
While there was some heterogeneity in the cDNA 5' termini, essentially identical results for both lines were obtained, with all the transcripts containing 5'-untranslated regions (UTRs) with exon -1b sequence (data not shown). There were no sequence differences between the 5'-RACE products and the published Genbank sequence for human CBS (Accession #: AF042836). The different levels of CBS transcripts between CMK and CMS cells were likely due to differences in promoter activity since transient transfections with the full length CBS -1b luciferase reporter gene construct resulted in approximately 40-fold greater promoter activity in the CMK cells than in CMS cells. [ Figure 1C ]
Ara-C Metabolism and Sensitivity in CMK and CMS Cells
For the CMK cells, overexpression of CBS was accompanied by ~10-fold greater in vitro ara-C sensitivity measured by the growth inhibition assay compared to the CMS cell line. (Figure 1, panel D) .
The increased ara-C sensitivity of the CMK cell line was accompanied by a 2.4-fold increased generation in vitro of 3 H-ara-CTP after 3 hour incubations with 3 H-ara-C compared to the CMS cell line. (Figure 1, panel D) .
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These results validate the CMK and CMS sublines as clinically relevant AML models to study the transcriptional regulation of the human CBS gene, and the mechanisms that result in the differential CBS expression in DS and non-DS AML samples. EMSAs were used to establish whether there were differences in transcription factor binding to the basal and upstream regions of the CBS -1b promoter that account for differential CBS expression in CMK and CMS cells. Synthetic FPA, FPB, FPC, FPD double stranded oligonucleotides (Table 1) were designed based on our previous findings of protected regions on DNase I footprints of the CBS -1b promoter in HepG2 cells. [15] Additional oligonucleotides [-3766/-3725 and -3724/-3682; Table 1] were designed for the basal CBS -1b promoter region. [16] Oligonucleotides were labeled by γ-32 P-ATP and incubated with nuclear extracts prepared from CMK and CMS cells. Nuclear extracts from the HepG2 cells, in which DNA/protein complexes were previously identified by oligonucleotide competitions and supershift assays [15, 16] , were used as controls. Competitions with unlabeled Sp1, USF1, or NF-Y consensus oligonucleotides were also performed in CMK and CMS cells to confirm the identities of the specific complexes (data not shown). 
In Vitro
Functional Analysis of Transcription Factor Binding Sites by Site-Directed Mutagenesis
Based on the EMSA results, the relevant Sp1/Sp3 consensus elements in the CBS -1b upstream region and the critical USF-1 and NF-Y consensus elements in the CBS -1b basal promoter region were mutated individually using the single stranded mutant oligonucleotides as primers. [ Table 1 
DISCUSSION
Identifying the biological basis for the extremely high EFS rates of DS AML patients treated with ara-C-based protocols, may lead to improvements in the treatment of AML, which has the worse prognosis of all childhood leukemias. Our prior studies provided compelling evidence that the chromosome 21-localized gene, CBS, plays a crucial role contributing to the enhanced ara-C sensitivity of DS myeloblasts and CBS-transfected leukemia cell line models. [11, 12, 13] Pronounced variations in CBS expression between DS and non-DS myeloblasts, [12] exceeding levels predicted by gene copy only.
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In view of the limitations in performing gene transcription studies with primary clinical leukemia samples, identification of relevant cell line models representative of clinical AML is essential. In this study, we selected two pediatric AMkL cell lines as representative leukemia models, to examine the transcriptional regulation of CBS based on the significant differences in CBS transcripts between the DS and non-DS AML, and the high frequency of the AMkL phenotype in DS AML cases. [10] Contrary to the clinical outcome of DS AMkL cases, non-DS AMkL cases have an extremely poor prognosis (cure rates <25%) as reported by both the Children's Cancer Group (CCG) and St. Jude Children's Research Hospital, [5, 21] thus highlighting distinct biologic differences between DS and non-DS AMkL cases. The DS cell line, CMK, generated 2.4-fold higher levels of ara-CTP and exhibited a 10-fold greater ara-C sensitivity compared to the non-DS CMS cell line, thus closely approximating our findings with DS and non-DS clinical AML samples and those with a CBS transfected CCRF-CEM cell line. [12, 13] We previously characterized the CBS -1b minimal (basal) promoter (-3792 to -3667) in HepG2 hepatocarcinoma cells and demonstrated that the transcription factors Sp1/Sp3, NF-Y and USF-1 were important transactivators of the basal promoter, and that the synergistic activation of the promoter involved Sp1/Sp3 and NF-Y. The critical cis elements and transcription factors in the upstream region were also examined in HT1080 and HepG2 cell line models, characterized by significant differences in CBS transcript levels, to better identify determinants of cell-specific expression of CBS. [15, 16] The results of these studies were extrapolated herein to the study of clinically relevant AMkL cell lines.
Analysis of the upstream region of the CBS -1b promoter by EMSAs demonstrated significant differences in binding of Sp1/Sp3 to the GC-f and GT-d elements in CMK cells compared to CMS cells.
The significance of these two binding sites was confirmed by mutation analysis, which resulted in only.
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approximately 90% decreased CBS -1b promoter activity. There were no significant differences in transcription factor binding to the basal CBS -1b promoter between the cell lines to account for the differences in CBS expression.
Based on prior studies of Sp factor phosphorylation in CBS -1b promoter transactivation, we assessed the effects of treating CMK nuclear extracts with CIP on Sp1/Sp3 binding in in vitro assays.
Indeed, CIP treatment markedly decreased Sp factor binding, strongly suggesting that the differential binding to the CBS -1b promoter is due to differences in phosphorylation of this critical transcription factor. Although we did not find increased binding of Sp1/Sp3 to the CBS promoter in CMS nuclear extracts following treatment with protein kinase A, other phosphorylation pathways or alternative mechanisms may be involved.
Interestingly, abnormal phosphorylation of a variety of proteins has been demonstrated in a number of DS studies and at least 2 genes have been identified on chromosome 21 that may lead to altered patterns of protein phosphorylation. [22, 23] The human homologue of the Drosophila minibrain gene, DYRK (dual specificity tyrosine phosphorylation regulated kinase) is localized to 21q22.2 and is believed to be involved in abnormal neurologic development of DS and can phosphorylate serine/threonine residues in protein substrates. [22] In DS cerebellum, elevated protein levels of the voltage-dependent anion-selective channel proteins (VDADs) were identified which regulate fluxes of anionic metabolites including ATP. [23] Although it has been postulated that the DS phenotype is due to the presence of genes on the long arm of chromosome 21 (known collectively as the Down Syndrome critical region) which are expressed in trisomy 21 cells at 1.5-fold higher levels compared to diploid cells, a variety of genes in DS are expressed at levels not based on a gene dosage effect. [24, 25, 26] only.
